Riskpilot← Back to searchSign inGet full accessVesiclebio AB
ABActiveOrg 5592834609Furugatan 7Research and experimental development on natural sciences and engineering · NACE 7210Est. 20201 employees
Revenue 2024
SEK 1,6M
-7% vs 2023
EBITDA margin
19.5%
+72% vs 2023
Equity ratio
47.5%
Financial strength
Net profit 2024
SEK 244K
+166% vs 2023
| Revenue | SEK 1,6M | -7% |
| EBITDA | SEK 316K | +72% |
| Net profit | SEK 244K | +166% |
| Total assets | SEK 2,4M | +2% |
| Equity | SEK 1,2M | -5% |
| Employees | 1 | — |
Legal name
Vesiclebio AB
Org number
5592834609
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16 november 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva verksamhet inom området biomedicin och kultur, inklusive undervisning och konsultationer, samt därmed förenlig verksamhet.
Address
Furugatan 7
Email
jan.lotvall@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 1 654 | 4 109 | 1 742 | 1 624 |
| Staff expenses | — | −979 | −1 072 | −837 |
| EBITDA | 886 | 2 501 | 184 | 316 |
| Depreciation & amort. | −0 | — | — | — |
| EBIT | 886 | 2 501 | 184 | 316 |
| Net financials | 1 | 1 | −8 | 2 |
| Profit before tax | 664 | 1 877 | 124 | 318 |
| Tax | −144 | −387 | −33 | −74 |
| Net profit | 520 | 1 490 | 92 | 244 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 1 238 | 3 238 | 2 392 | 2 435 |
| Equity | 545 | 1 675 | 1 215 | 1 156 |
| Long-term debt | 0 | — | — | — |
| Short-term debt | 470 | 715 | 277 | 379 |
| Total debt | 470 | 715 | 277 | 379 |
EBITDA margin
19.5%
This company
15.8%
Market median
+23% vs market
20212024
Equity ratio
47.5%
This company
38.2%
Market median
+24% vs market
20212024
Return on equity
21.1%
This company
18.4%
Market median
+15% vs market
20212024
Net profit margin
15.0%
This company
8.1%
Market median
+85% vs market
20212024
Asset turnover
0.67×
This company
1.12×
Market median
-40% vs market
20212024
Debt / equity
1.11×
This company
0.62×
Market median
-79% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-11-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (4) | ||
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Vesiclebio AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Jan Olof Lötvall | Board of Directors | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Nina Marika Wodzinski | Board of Directors | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |
| Maria Cecilia Andersson Lötvall | Deputy Board Member | 0 companies |